Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study

Two recent phase 3 trials showed that outcomes for relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) patients may be improved by a single-agent tyrosine kinase inhibitor (TKI) (i.e., quizartinib or gilteritinib). In the current study, we retrospectively investigated the characteris...

Descripción completa

Detalles Bibliográficos
Autores principales: Dumas, Pierre-Yves, Bertoli, Sarah, Bérard, Emilie, Largeaud, Laetitia, Bidet, Audrey, Delabesse, Eric, Leguay, Thibaut, Leroy, Harmony, Gadaud, Noémie, Rieu, Jean Baptiste, Vial, Jean-Philippe, Vergez, François, Lechevalier, Nicolas, Luquet, Isabelle, Klein, Emilie, Sarry, Audrey, de Grande, Anne-Charlotte, Pigneux, Arnaud, Récher, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465142/
https://www.ncbi.nlm.nih.gov/pubmed/32722211
http://dx.doi.org/10.3390/cancers12082044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465142/
https://www.ncbi.nlm.nih.gov/pubmed/32722211
http://dx.doi.org/10.3390/cancers12082044

Ejemplares similares